Advertisement

Breast Cancer Research and Treatment

, Volume 106, Issue 1, pp 75–84 | Cite as

Reduction in proliferation with six months of letrozole in women on hormone replacement therapy

  • Carol J. Fabian
  • Bruce F. Kimler
  • Carola M. Zalles
  • Qamar J. Khan
  • Matthew S. Mayo
  • Teresa A. Phillips
  • Marie Simonsen
  • Trina Metheny
  • Brian K. Petroff
Clinical Trial

Abstract

The objective of this study was to determine if 6 months of the aromatase inhibitor letrozole, administered to postmenopausal women taking a stable dose of hormone replacement remedy, would be safe and would modulate biomarkers of breast cancer risk. The intent was to reduce the proliferation marker Ki-67 while maintaining adequate systemic levels of estradiol so as to avoid perimenopausal symptoms. Postmenopausal women at high risk for development of breast cancer and taking a stable dose of estrogen or estrogen plus progestin were screened by random periareolar fine needle aspiration (RPFNA). To be eligible, the acquired breast epithelial cells had to be characterized as cytologic atypia or borderline atypia with ≥1,000 epithelial cells on the cytomorphology slide; plus ≥500 epithelial cells on a slide processed for Ki-67 immunocytochemistry. Forty-two women were enrolled in the one arm study and received 2.5 mg letrozole per day for 6 months, followed by repeat assessment of biomarkers. Ki-67 was reduced by a median relative value of 66%. There was no significant change in breast cell cytomorphology; ER weighted index score; serum estradiol, testosterone, or IGF-1:IGFBP-3 ratio; mammographic breast density, or frequency or severity of perimenopausal symptoms. Given the dramatic reduction in proliferation, the effect of letrozole on risk and response biomarkers should be explored further in a randomized, placebo-controlled Phase IIB breast cancer chemoprevention trial.

Keywords

Random periareolar fine needle aspiration RPFNA Breast cancer Chemoprevention 

References

  1. 1.
    National Institutes of Health (2005) National institutes of health state-of-the-science conference statement: management of menopause-related symptoms. Ann Intern Med 142:1003–1013Google Scholar
  2. 2.
    Barton DL, Loprinzi C, Gostout B (2002) Current management of menopausal symptoms in cancer patients. Oncology (Williston Park) 16:67–72, 74Google Scholar
  3. 3.
    Nelson HD (2004) Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 291:1610–1620PubMedCrossRefGoogle Scholar
  4. 4.
    Fabian CJ, Kimler BF (2005) Selective estrogen–receptor modulators for primary prevention of breast cancer. J Clin Oncol 23:1644–1655PubMedCrossRefGoogle Scholar
  5. 5.
    Cuzick J (2005) Aromatase inhibitors for breast cancer prevention. J Clin Oncol 23:1636–1643PubMedCrossRefGoogle Scholar
  6. 6.
    Wickerham DL, Costantino JP, Vogel P, Cronin W, Cecchini R, Atkins J, Bevers T, Fehrenbacher L, McCaskill-Stevens W, Wolmark N (2006) The study of tamoxifen and raloxifene (STAR): initial findings from the NSABP P-2 breast cancer prevention study. J Clin Oncol 24(18S):2s (abstract LBA5)Google Scholar
  7. 7.
    Vogel VG (2001) Reducing the risk of breast cancer with tamoxifen in women at increased risk. J Clin Oncol 19(18 Suppl):87S–92SPubMedGoogle Scholar
  8. 8.
    Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG III, Burstein HJ, Eisen A, Lipkus I, Pfister DG (2002) American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 20:3328–3343PubMedCrossRefGoogle Scholar
  9. 9.
    Port ER, Montgomery LL, Heerdt AS, Borgen PI (2001) Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 8:580–585PubMedCrossRefGoogle Scholar
  10. 10.
    Vogel VG, Costantino JP, Wickerham DL, Cronin WM (2002) Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 94:1504PubMedGoogle Scholar
  11. 11.
    Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M (2004) Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 100:1800–1806PubMedCrossRefGoogle Scholar
  12. 12.
    Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM (2004) Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 22:4951–4957PubMedCrossRefGoogle Scholar
  13. 13.
    Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM (2004) Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092PubMedCrossRefGoogle Scholar
  14. 14.
    Thurlimann BJ, Keshaviah A, Mouridsen H, Mauriac L, Forbes JF, Parideans R, Castiglione-Gertsch M, Gelber RD, Smith I, Goldhirsch A (2005) BIG 1-98: randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. J Clin Oncol ASCO Ann Mtg Proc 23:6s (abstract 511)Google Scholar
  15. 15.
    Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS (2005) ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62PubMedCrossRefGoogle Scholar
  16. 16.
    Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 22:4261–4271PubMedCrossRefGoogle Scholar
  17. 17.
    Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802PubMedCrossRefGoogle Scholar
  18. 18.
    Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE (2006) Duration of letrozole treatment, outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 99:295–300PubMedCrossRefGoogle Scholar
  19. 19.
    Miller WR, O’Neill J (1987) The importance of local synthesis of estrogen within the breast. Steroids 50:537–548PubMedCrossRefGoogle Scholar
  20. 20.
    Brueggemeier RW, Richards JA, Petrel TA (2003) Aromatase and cyclooxygenases: enzymes in breast cancer. J Steroid Biochem Mol Biol 86:501–507PubMedCrossRefGoogle Scholar
  21. 21.
    Tekmal RR, Kirma N, Gill K, Fowler K (1999) Aromatase overexpression and breast hyperplasia, an in vivo model—continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands. Endocr Relat Cancer 6:307–314PubMedCrossRefGoogle Scholar
  22. 22.
    Kirma N, Gill K, Mandava U, Tekmal RR (2001) Overexpression of aromatase leads to hyperplasia and changes in the expression of genes involved in apoptosis, cell cycle, growth, and tumor suppressor functions in the mammary glands of transgenic mice. Cancer Res 61:1910–1918PubMedGoogle Scholar
  23. 23.
    Luthra R, Kirma N, Jones J, Tekmal RR (2003) Use of letrozole as a chemopreventive agent in aromatase overexpressing transgenic mice. J Steroid Biochem Mol Biol 86:461–467PubMedCrossRefGoogle Scholar
  24. 24.
    Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Kamel S, Zeiger S, Mayo MS (2000) Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 92:1217–1227PubMedCrossRefGoogle Scholar
  25. 25.
    Shaaban AM, Sloane JP, West CR, Foster CS (2002) Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol 160:597-604PubMedGoogle Scholar
  26. 26.
    Khan QJ, Kimler BF, Clark J, Metheny T, Zalles CM, Fabian CJ (2005) Ki-67 Expression in benign breast ductal cells obtained by random periareolar fine needle aspiration. Cancer Epidemiol Biomarkers Prev 14:1–4CrossRefGoogle Scholar
  27. 27.
    Petroff BK, Clark JL, Metheny T, Xue Q, Kimler BF, Fabian CJ (2006) Optimization of estrogen receptor analysis by immunocytochemistry in random periareolar fine needle aspirates of benign breast tissue processed using thin layer preparation technology. Appl Immunohist Mol Morph 14:360–364CrossRefGoogle Scholar
  28. 28.
    Boyd NF, Lockwood GA, Bying JW, Tritchler DL, Yaffe MJ (1998) Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7:1133–1144PubMedGoogle Scholar
  29. 29.
    Key T, Appleby P, Barnes I, Reeves G (2002) Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616PubMedGoogle Scholar
  30. 30.
    Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, Olsen A, Tjonneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Tehard B, Nagel G, Linseisen J, Boeing H, Lahmann PH, Trichopoulou A, Trichopoulos D, Koliva M, Palli D, Panico S, Tumino R, Sacerdote C, van Gils CH, van Noord P, Grobbee DE, Bueno-de-Mesquita HB, Gonzalez CA, Agudo A, Chirlaque MD, Barricarte A, Larranaga N, Quiros JR, Bingham S, Khaw KT, Key T, Allen NE, Lukanova A, Slimani N, Saracci R, Riboli E, Kaaks R (2006) IGF-I, IGFBP-3 and breast cancer risk in women: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 13:593–605PubMedCrossRefGoogle Scholar
  31. 31.
    Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer—a study from the IMPACT trialists. J Clin Oncol 23:2477–2492PubMedCrossRefGoogle Scholar
  32. 32.
    Gail MH, Briton LA, Byar DP, Corle DK, Green SB, Schair C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886PubMedCrossRefGoogle Scholar
  33. 33.
    Zalles C, Kimler BF, Kamel S, McKittrick R, Fabian CJ (1995) Cytologic patterns in random aspirates from women at high and low risk for breast cancer. Breast J 1:343–349CrossRefGoogle Scholar
  34. 34.
    Masood S, Frykberg ER, McLellan GL, Scalapino MC, Mitchum DG, Bullard JB (1990) Prospective evaluation of radiologically directed fine-needle aspiration biopsy of nonpalpable breast lesions. Cancer 66:1480–1487PubMedCrossRefGoogle Scholar
  35. 35.
    Zalles CM, Kimler BF, Simonsen M, Clark JL, Metheny T, Fabian CJ (2006) Comparison of cytomorphology in specimens obtained by random periareolar fine needle aspiration and ductal lavage from women at high risk for development of breast cancer. Breast Cancer Res Treat 97:191–197PubMedCrossRefGoogle Scholar
  36. 36.
    The uniform approach to breast fine-needle aspiration biopsy (1997) National Cancer Institute Fine-Needle Aspiration of Breast Workshop Subcommittees. Diagn Cytopathol 16:295–311Google Scholar
  37. 37.
    Petroff BK, Philips TA, Kimler BF, Fabian CJ (2006) Detection of biomarker gene expression by real-time polymerase chain reaction using amplified ribonucleic acids from formalin-fixed random periareolar fine needle aspirates of human breast tissue. Anal Quant Cytol Histol 28:297–302PubMedGoogle Scholar
  38. 38.
    Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C (2001) An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25:386–401PubMedCrossRefGoogle Scholar
  39. 39.
    Feldman AL, Costouros NG, Wang E, Qian M, Marincola FM, Alexander HR, Libutti SK (2002) Advantages of mRNA amplification for microarray analysis. Biotechniques 33:906–912PubMedGoogle Scholar
  40. 40.
    Gjerdrum LM, Sorensen BS, Kjeldsen E, Sorensen FB, Nexo E, Hamilton-Dutoit S (2004) Real-time PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. J Mol Diagn 6:42–51PubMedGoogle Scholar
  41. 41.
    Goldsworthy SM, Stockton PS, Trempus CS, Foley JF, Maronpot RR (1999) Effects of fixation on RNA extraction and amplification from laser capture microdissected tissue. Mol Carcinogen 25:86–91CrossRefGoogle Scholar
  42. 42.
    Liss B (2002) Improved quantitative real-time RT-PCR for expression profiling of individual cells. Nucleic Acids Res 30:e89Google Scholar
  43. 43.
    Al-Taher A, Bashein A, Nolan T, Hollingsworth M, Brady G (2000) Global cDNA amplification combined with real-time RT-PCR: accurate quantification of multiple human potassium channel genes at the single cell level. Yeast 17:201–210PubMedCrossRefGoogle Scholar
  44. 44.
    Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408PubMedCrossRefGoogle Scholar
  45. 45.
    De-Cremoux P, Tran-Perennou C, Brockdorff BL, Boudou E, Brunner N, Magdelenat H, Lykkesfeldt AE (2003) Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens. Endocr Rel Canc 10:409–418CrossRefGoogle Scholar
  46. 46.
    England BG, Niswender GD, Midgley AR Jr (1974) Radioimmunoassay of estradiol-17β without chromatography. J Clin Endocrinol Metab 38:42–50PubMedCrossRefGoogle Scholar
  47. 47.
    Pearce S, Dowsett M, Jeffcoate SL (1989) Three methods compared for estimating the fraction of testosterone and estradiol not bound to sex-hormone-binding globulin. Clin Chem 35:632–635PubMedGoogle Scholar
  48. 48.
    Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, Lockwood GA, Tritchler DL, Yaffe MJ (1995) Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 87:670-675PubMedCrossRefGoogle Scholar
  49. 49.
    Stone J, Gunasekara A, Martin LJ, Yaffe M, Minkin S, Boyd NF (2003) The detection of change in mammographic density. Cancer Epidemiol Biomarkers Prev 12: 625–630PubMedGoogle Scholar
  50. 50.
    Loprinzi L, Barton DL, Sloan JA, Zahasky KM, de Smith AR, Pruthi S, Novotny PJ, Perez EA, Christensen BJ (2002) Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 77:1159–1163PubMedCrossRefGoogle Scholar
  51. 51.
    Bartels PH, Fabian CJ, Kimler BF, Ranger Moore J, Frank D, Yozwiak M, Alberts D (2007) Karyometry of breast epithelial cells acquired by random periareolar fine needle aspiration of women at high risk for breast cancer. Anal Quant Cytol Histol (in press)Google Scholar
  52. 52.
    Harper-Wynne CL, Sacks NP, Shenton K, MacNeill FA, Sauven P, Laidlaw IJ, Rayter Z, Miall S, Howes A, Salter J, Hills MJ, Lowe FM, A’Hern R, Nasiri N, Doody D, Iqbal J, Dowsett M (2002) Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 20:1026–1035PubMedCrossRefGoogle Scholar
  53. 53.
    Harper-Wynne C, Ross G, Sacks N, Salter J, Nasiri N, Iqbal J, A’Hern R, Dowsett M (2002) Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 11:614–621PubMedGoogle Scholar
  54. 54.
    Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23:7212–7220PubMedCrossRefGoogle Scholar
  55. 55.
    Bonanni B, Johansson H, Gandini S, Guerrieri-Gonzaga A, Torrisi R, Sandri MT, Cazzaniga M, Mora S, Robertson C, Lien EA, Decensi A (2001) Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. Breast Cancer Res Treat 69:21–27PubMedCrossRefGoogle Scholar
  56. 56.
    Heald A, Selby PL, White A, Gibson JM (2000) Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. Am J Obstet Gynecol 183:593–600PubMedCrossRefGoogle Scholar
  57. 57.
    Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE (2000) Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 60: 3744–3748PubMedGoogle Scholar
  58. 58.
    Boyd NF, Jensen HM, Cooke G, Han HL (1992) Relationship between mammographic and histological risk factors for breast cancer. J Natl Cancer Inst 84:1170–1179PubMedCrossRefGoogle Scholar
  59. 59.
    Boyd NF, Stone J, Martin LJ, Jong R, Fishell E, Yaffe M, Hammond G, Minkin S (2002) The association of breast mitogens with mammographic densities. Br J Cancer 87:876–882PubMedCrossRefGoogle Scholar
  60. 60.
    Warren R, Skinner J, Sala E, Denton E, Dowsett M, Folkerd E, Healey CS, Dunning A, Doody D, Ponder B, Luben RN, Day NE, Easton D (2006) Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women. Cancer Epidemiol Biomarkers Prev 15:1502–1508PubMedCrossRefGoogle Scholar
  61. 61.
    Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW (2004) Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96:621–628PubMedCrossRefGoogle Scholar
  62. 62.
    Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CHJ, Ferraro JA, Zalles CM, Stanton AL, Masood S, Grizzle WE, Boyd NF, Arneson DW, Johnson KA (2002) A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 8:3105–3117PubMedGoogle Scholar
  63. 63.
    Mohsin SK, Allred DC, Osborne CK, Cruz A, Otto P, Chew H, Clark GM, Elledge RM (2005) Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer. Breast Cancer Res Treat 94:205–211PubMedCrossRefGoogle Scholar
  64. 64.
    Fabian CJ, Kimler BF, Anderson JR, Chamberlain C, Mayo MS, Zalles CM, O’Shaughnessy JA, Lynch HT, Johnson KA, Browne D (2006) Phase II breast cancer chemoprevention trial of the third generation selective estrogen receptor modulator arzoxifene. J Clin Oncol 24(Suppl 18S):49s (abstract 1001)Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Carol J. Fabian
    • 1
  • Bruce F. Kimler
    • 2
  • Carola M. Zalles
    • 3
  • Qamar J. Khan
    • 1
  • Matthew S. Mayo
    • 4
  • Teresa A. Phillips
    • 1
  • Marie Simonsen
    • 1
  • Trina Metheny
    • 1
  • Brian K. Petroff
    • 1
  1. 1.Department of Internal MedicineUniversity of Kansas Medical CenterKansas CityUSA
  2. 2.Department of Radiation OncologyUniversity of Kansas Medical CenterKansas CityUSA
  3. 3.Yale UniversityNew HavenUSA
  4. 4.Department of Preventive MedicineUniversity of Kansas Medical CenterKansas CityUSA

Personalised recommendations